What is claimed is:

1. Use of an antibody that immunospecifically binds folate receptor alpha (FRA) in the preparation of a medicament for treatment of a patient having a FRA-expressing lung cancer, wherein the patient's FRA expression level equals or exceeds a reference FRA expression level.

2. The use according to claim 1, wherein said reference FRA expression level corresponds to the FRA expression level above which a patient population afflicted with said FRA-expressing lung cancer that is administered said antibody that immunospecifically binds FRA demonstrated a statistically significant improvement in at least one clinical outcome relative to a patient population afflicted with said FRA-expressing lung cancer that is administered placebo.

3. The use according to claim 2, wherein said patient populations were further administered a chemotherapeutic agent.

4. The use according to claim 3, wherein said chemotherapeutic agent comprises a taxane, cisplatin, carboplatin, and/or pemetrexed.

5. The use according to any preceding claim, wherein said FRA expression level is measured by protein quantification or RNA quantification.

6. The use according to any one of claims 1 to 5, wherein said FRA expression level is measured by immunohistochemical analysis.

7. The use according to any one of claims 1 to 5,–wherein said FRA expression level is cytoplasmic FRA expression.

8. The use according to any one of claims 1 to 5, wherein said FRA expression level is membranous FRA expression.

9. The use according to any one of claims 1 to 5, wherein said antibody that immunospecifically binds FRA is conjugated to a toxin.

10. The use according to claim 9, wherein said toxin comprises a microtubule inhibitor, a DNA damaging agent, a DNA repair inhibitor, or a signal transduction inhibitor.

11. The use according to claim 10, wherein said DNA damaging agent comprises a radionuclide.

12. The use according to any one of claims 1 to 5, wherein said antibody that immunospecifically binds FRA is:

an antibody comprising SEQ ID NO:1 as CDRH1, SEQ ID NO:2 as CDRH2, SEQ ID NO:3 as CDRH3, SEQ ID NO:4 as CDRL1, SEQ ID NO:5 as CDRL2 and SEQ ID NO:6 as CDRL3;

an antibody comprising a mature light chain variable region comprising the amino acid sequence of SEQ ID NO:7 and/or a mature heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 8;

farletuzumab;

an antibody that specifically binds to folate receptor alpha comprising a mature light and heavy chain variable regions having at least 90% and preferably at least 95% or 99% sequence identity to SEQ ID NO: 7 and SEQ ID NO: 8, respectively; or

an antibody or derivative thereof can competitively inhibit binding of farletuzumab to folate receptor alpha.

13. The use according to any one of claims 1 to 5, wherein the treatment further comprises a therapeutically effective amount of a chemotherapeutic agent.

14. The use according to claim 13, wherein said chemotherapeutic agent comprises a platinum-containing compound.

15. The use according to claim 14, wherein said platinum-containing compound comprises cisplatin or carboplatin.

16. The use according to any one of claims 1 to 5, wherein the treatment further comprises a therapeutically effective amount of a taxane.

17. The use according to claim 16, wherein said taxane is paclitaxel.

18. The use according to claim 14 or 15, wherein the treatment further comprises a therapeutically effective amount of a taxane.

19. The use according to claim 18, wherein said taxane is paclitaxel.

20. The use according to claim 14, 15, 17, or 19, wherein the treatment further comprises a therapeutically effective amount of pemetrexed.

21. The use according to any one of claims 1 to 5, wherein the treatment further comprises therapeutically effective amounts of carboplatin and paclitaxel.

22. The use according to claim 21, wherein the dose of paclitaxel is about 50 mg/m^2 to about 250 mg/m^2.

23. The use according to any one of claims 1 to 5, wherein the treatment further comprises therapeutically effective amounts of carboplatin and pemetrexed.

24. The use according to claim 23, where the dose of pemetrexed is about 400 to about 600 mg/m^2.

25. The use according to any one of claims 1 to 5, wherein the treatment further comprises therapeutically effective amounts of cisplatin and pemetrexed.

26. The use according to claim 25, wherein the dose of cisplatin is about 50 mg/m^2 to about 250 mg/m^2.

27. The use according to claim 25, wherein the dose of pemetrexed is about 400 mg/m^2 to about 600 mg/m^2.

28. The use according to any one of claims 1 to 5 wherein said FRA expression level is determined by immunoassay with at least one of the following antibodies:

(a) an antibody that binds the same epitope as farletuzumab;

(b) an antibody comprising SEQ ID NO:1 (GFTFSGYGLS) as CDRH1, SEQ ID NO:2 (MISSGGSYTYYADSVKG) as CDRH2, SEQ ID NO:3 (HGDDPAWFAY) as CDRH3, SEQ ID NO:4 (SVSSSISSNNLH) as CDRL1, SEQ ID NO:5 (GTSNLAS) as CDRL2 and SEQ ID NO:6 (QQWSSYPYMYT) as CDRL3;

(c) an antibody comprising a mature light chain variable region comprising the amino acid sequence of SEQ ID NO:7 and a mature heavy chain variable region comprising the amino acid SEQ ID NO: 8;

(d) farletuzumab;

(e) the 548908 antibody;

(f) an antibody that binds the same epitope as the 548908 antibody;

(g) the 6D398 antibody;

(h) an antibody that binds the same epitope as the 6D398 antibody;

(i) the BN3.2 antibody;

(j) an antibody that binds the same epitope as the BN3.2 antibody;

(k) an antibody that binds the same epitope as the 26B3 antibody;

(l) an antibody comprising SEQ ID NO: 14 (GYFMN) as CDRH1, SEQ ID NO: 15 (RIFPYNGDTFYNQKFKG) as CDRH2, SEQ ID NO: 16 (GTHYFDY) as CDRH3, SEQ ID NO: 17 (RTSENIFSYLA) as CDRL1 , SEQ ID NO: 18 (NAKTLAE) as CDRL2 and SEQ ID NO: 19 (QHHYAFPWT) as CDRL3;

(m) the 26B3 antibody;

(n) an antibody that binds the same epitope as the 19D4 antibody;

(o) an antibody comprising SEQ ID NO: 20 (HPYMH) as CDRH1, SEQ ID NO: 21 (RIDPANGNTKYDPKFQG) as CDRH2, SEQ ID NO: 22 (EEVADYTMDY) as CDRH3, SEQ

ID NO: 23 (RASESVDTYGNNFIH) as CDRL1, SEQ ID NO: 24 (LASNLES) as CDRL2 and SEQ ID NO: 25 (QQNNGDPWT) as CDRL3;

(p) the 19D4 antibody;

(q) an antibody that binds the same epitope as the 9F3 antibody;

(r) an antibody comprising SEQ ID NO: 26 (SGYYWN) as CDRH1, SEQ ID NO: 27 (YIKSDGSNNYNPSLKN) as CDRH2, SEQ ID NO: 28 (EWKAMDY) as CDRH3, SEQ ID NO: 29 (RASSTVSYSYLH) as CDRL1, SEQ ID NO: 30 (GTSNLAS) as CDRL2 and SEQ ID NO: 31 (QQYSGYPLT) as CDRL3;

(s) the 9F3 antibody;

(t) an antibody that binds the same epitope as the 24F12 antibody;

(u) an antibody comprising SEQ ID NO: 32 (SYAMS) as CDRH1, SEQ ID NO: 33 (EIGSGGSYTYYPDTVTG) as CDRH2, SEQ ID NO: 34 (ETTAGYFDY) as CDRH3, SEQ ID NO: 35 (SASQGINNFLN) as CDRL1, SEQ ID NO: 36 (YTSSLHS) as CDRL2 and SEQ ID NO: 37 (QHFSKLPWT) as CDRL3;

(v) the 24F12 antibody;

(w) an antibody that comprises a variable region light chain selected from the group consisting of:

(i) LK26HuVK;

(ii) LK26HuVKY;

(iii) LK26HuVKPW; and

(iv) LK26HuVKPW,Y;

(x) an antibody that comprises a variable region heavy chain selected from the group consisting of:

(i) LK26HuVH;

(ii) LK26HuVH FAIS,N;

(iii) LK26HuVH SLF;

(iv) LK26HuVH I,I;

(v) LK26KOLHuVH;

(y) an antibody that comprises the heavy chain variable region LK26KOLHuVH (SEQ ID NO: 46) and the light chain variable region LK26HuVKPW,Y (SEQ ID NO: 41);

(z) an antibody that comprises the heavy chain variable region LK26HuVH SLF (SEQ ID NO: 44) and the light chain variable region LK26HuVKPW,Y (SEQ ID NO: 41);

(aa) an antibody that comprises the heavy chain variable region LK26HuVH FAIS,N (SEQ ID NO: 43) and the light chain variable region LK26HuVKPW,Y (SEQ ID NO: 41); and

(bb) the murine monoclonal LK26 antibody.

29. The use according to any one of claims 1 to 5 wherein said patient's FRA expression level is assessed by digital imaging technology or manual pathology quantification.

30. The use according to claim 5, wherein said patient's FRA expression level is assessed by FRAMSCOR or HBSCOR.

31. The use according to claim 30, wherein said reference FRA expression level is 42% +1 or greater anti-FRA staining.

32. The use according to claim 30, wherein said reference FRA expression level is 21% +2 or greater anti-FRA staining.

33. The use according to claim 30, wherein said reference FRA expression level is 14% +3 or greater staining.

34. The use according to claim 30, wherein said reference FRA expression level is a FRAMSCOR of 7.

35. The use according to claim 30, wherein said reference FRA expression level is a HBSCOR of 0.25.

36. The use according to any one of claims 1 to 5, wherein said biological sample is whole blood, serum, plasma, circulating cells, circulating tumor cells, free cells, tissue, pleural effusion, urine, saliva, sputum, or bronchial washing.

37. The use according to any one of claims 1 to 5, wherein said biological sample comprises pleural tissue.

38. The use according to any one of claims 1 to 5, wherein said biological sample comprises pleural cells derived from effusion.

39. The use according to claim 2, wherein said at least one clinical outcome is progression free survival and/or overall survival.

40. The use according to any one of claims 1 to 5, wherein said FRA-expressing lung cancer is FRA-expressing non-small cell lung cancer (NSCLC).

41. The use according to claim 40, wherein said NSCLC is adenocarcinoma.